Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐cell lymphoma: Insights from real‐life clinical practice

Abstract Background Tumor lysis syndrome (TLS) is a potentially life‐threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures. TLS can be managed through hyperhydr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jasmine Mohamad, Antonin Bouroumeau, Thomas A. McKee, Nicolas Mach, Kaveh Samii, Martine Chamuleau, Frank Stenner, Jerome Tamburini, Noémie Lang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-10-01
coleção:	Cancer Reports
Assuntos:	aggressive B lymphoma rituximab tumor lysis syndrome
Acesso em linha:	https://doi.org/10.1002/cnr2.1983
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!